Teva
Teva in-licensed the exclusive rights for Circadin® for the treatment of primary insomnia in Israel and became a strategic partner. Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of ethical, generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.
With more than a century of experience in the healthcare industry, the Company enjoys a firmly established international presence, operating through a carefully tailored network of worldwide subsidiaries. Headquartered in Israel, above 80% of Teva’s sales, which totaled US$11.1 billion in 2008, are in North America and Europe. Teva has over 38,000 employees worldwide and production facilities in Israel, North America, Europe and Latin America.
For further information, please visit www.tevapharm.com
Takeda Pharmaceuticals International GmbH
Takeda is marketing Circadin® in Belgium, Netherlands, Greece, the Baltic States, Norway, Sweden, Finland, Denmark, Iceland and Luxembourg.
Takeda Pharmaceuticals International GmbH, headquartered in Zurich, is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As the largest pharmaceutical company in Japan and a leader in the global industry, Takeda’s mission is to strive toward better health for patients worldwide through leading innovation in medicine. It has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Takeda is ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. Takeda’s commercial presence mainly covers the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.
For further information, please visit www.takeda.com
Aspen Pharmacare
Aspen Pharmacare is marketing Circadin® in Australia and New Zealand.
Aspen Pharmacare Australia is a subsidiary of Aspen Pharmacare Holdings Limited, the largest listed pharmaceutical company in South Africa.
Aspen Pharmacare Australia commenced operations in May 2001 with a portfolio of products generating sales of $10.5 million. Its current annualized sales are over AU$ 230 million and growing.
For further information, please visit www.aspenpharma.com.au
DKSH
DKSH is marketing Circadin® in Thailand.
Diethelm Limited is a member of the DKSH Group, which formed following the mergers of three Swiss companies: Diethelm, Keller, and SiberHegner in 2000 and 2002.
Established in 1906 on the banks of Chao Phraya River, today the company is one of Thailand’s leading business organizations, with annual sales of THB 98 billion in 2008. It has over 10,000 employees and a comprehensive network of 203 branches all across the country. It is the largest marketing, distribution, and logistics service provider in Thailand.
For further information, please visit www.dksh.co.th
Pliva
Pliva is marketing Circadin® in Croatia.
Pliva, one of the biggest companies in Croatian economy with annual sales of HRK 2.5 billion, holds 88 years of tradition in drug manufacturing and 68 years of organized R&D. It has over 2,200 employees and holds the biggest share in the Croatian pharmaceutical market.
Since 2009, Pliva is a member of the Teva group, the biggest generic pharmaceutical company in the world.
For further information, please visit www.pliva.com
Luye Pharma
Luye Pharma is marketing Circadin® in China.
Luye Pharma is a leading specialty pharmaceutical group in the People’s Republic of China focusing on the research and development, production and sale of natural drugs, drugs with new delivery system and new drugs with other specific features.
For further information, please visit www.luye.cn
Kuhnil Pharm
Kuhnil Pharm is a pharmaceutical company established in Korea. The company speciliazes in manufacturing, distributing, importing, and exporting pharmaceutical products in the musculoskeletal, infection, cardiovascular, respiratory, CNS, endocrinological and allergy therapeutic areas.
For further information, please visit www.kuhnil.com
Desitin Arzneimittel
Desitin is marketing Circadin® in Germany.
Desitin Arzneimittel Gmbh was founded in Berlin in 1919.
In 1945, Desitin moved its operations to Hamburg and increasingly placed more focus on CNS products. This enabled the company to establish itself as a specialist supplier and competent partner in the field of epilepsy and also in the field of Parkinson’s disease.
Today Desitin is well established as a specialist in the field of epilepsy and Parkinson´s disease with additional expertise in CNS niche indications.
For further information, please visit www.desitinpharma.com
Flynn Pharma
Flynn Pharma is marketing Circadin® in UK & Ireland.
Flynn Pharma is a UK-based pharmaceutical company, incorporated in 2006, with significant presence in the UK and Ireland.
It is focused on hospital and specialty sectors and has a robust portfolio of over 60 marketed product lines in the UK & Ireland.
For further information, please visit www.flynnpharma.com
Italfarmaco
Italfarmaco is marketing Circadin® in Portugal.
Founded in June, 1999, Italfarmaco Portugal belongs to the Italfarmaco Group founded in 1938 in Milan, Italy. Today, the Italfarmaco group is present in several European countries and in the main markets in South America.
Since its foundation in 1999, Italfarmaco has been committed with its values: being ethic, offering health solutions, developing and providing high quality pharmaceutical products with scientific and technologic innovations.
For further information, please visit www.italfarmaco.it
Ipsen
Ipsen is marketing Circadin® in Russia.
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Its development strategy is supported by four franchises: neurology, endocrinology, uro-oncology and hemophilia. The company’s R&D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins.
For further information, please visit www.ipsen.com
